- Telo Genomics (TELO) appoints Dr. McGlennen as Board Director, a Leader in Commercializing Novel Diagnostic Technologies
- Dr. McGlennen brings over 30 years of leadership in the development and commercialization of innovative diagnostic and prognostic technologies
- He is internationally recognized as an expert in molecular biology and genetics
- He is currently Associate Professor of Pathology at the University of Minnesota Medical School
- Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry
- Telo Genomics Corp. (TELO) is trading at C$0.32 as of yesterday at 9:32 am EST
Telo Genomics Corp. (TELO) has welcomed Dr. Ron McGlennen, President and Founder of Access Genetics to its Board of Directors.
Dr. McGlennen brings unique and valuable expertise to TELO’s board with extensive experience in successfully introducing novel diagnostics technologies into clinical laboratories across the USA.
Dr. McGlennen brings over 30 years of leadership in the development and commercialization of innovative diagnostic and prognostic technologies across multiple disease areas.
He is internationally recognized as an expert in molecular biology and genetics. Over the past decades, Dr. McGlennen has acted as medical director of several clinical laboratories across the USA.
He is currently Associate Professor of Pathology at the University of Minnesota Medical School and has published more than 70 peer-reviewed publications and book chapters.
He holds nine issued and pending patents. He is board-certified in Anatomic and Clinical Pathology and also by the American Board of Medical Genetics, with a specialty in clinical molecular genetics.
Dr. McGlennen has also served on a series of governmental and regulatory committees focused on the growth of the field of molecular diagnostics.
“I have previously collaborated with Ron on diagnostics iniatives, and am thrilled that he is now joining the TELO Board of Directors,” said Guido Baechler, TELO Chairman.
“Dr. McGlennen brings over 30 years of clinical laboratory leadership, especially when it comes to introducing new technologies into clinical laboratory practice. His contribution will be invaluable to execute the commercialization plan for TELO’s multiple myeloma test into clinical practice,” added Baechler.
“I am excited to join the Telo Genomics Board of Directors,” said Ron McGlennen.
“The TeloView® technology is supported by robust evidence and has the potential to provide effective prognostic solutions to critical unmet needs in the management of multiple myeloma and potentially other cancers as well,” concluded McGlennen.
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions.
These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches.
Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.
Telo Genomics Corp. (TELO) is trading at C$0.32 as of yesterday at 9:32 am EST.
